OR WAIT 15 SECS
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Episode 45: Getting Drug Approval Through FDA LPAD
Christen Harm
Christen Harm is Pharmaceutical Executive's Associate Editor. Email her at charm@mmhgroup.com
Elaine Quilici
Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com
Pharmaceutical Executive
William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.
William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Related Content:
Editorial Podcasts